Development of a Preclinical 3D Vascularized and Perfused Tumoroid Model in Oncology and Urology Developed From Patient Tumors (Kidney, Bladder, and Prostate Cancers)

Condition(s) studied

Investigational drug(s) / intervention(s)

Blood sample: An additional 10 ml blood sample taken during a routine blood test

Study summary

This is a study :

* Single-center
* Prospective
* Translational
* Based on data and blood samples. In this context, the aim is to collect approximately 10 ml of blood from each patient included in the 3D tumoroid development project.

The main objective is to establish and validate a panel of vascularized and perfused 3D tumoroids for personalized medicine based on patient tumors for urological cancers, incorporating autologous immune cells.

Translated with DeepL.com (free version)

Eligibility

Primary outcome measure(s)

• Constitute and validate a panel of vascularized and perfused 3D tumoroids for personalized medicine based on patient tumors for urological cancers, incorporating autologous immune cells. — Day 1 after surgery
  For the establishment of the models, it is necessary to have: sufficient cell viability after enzymatic dissociation of the tissues and a correspondence of patient/model 3D therapeutic responses. The patients' blood will be collected to isolate immune cells using a Ficoll gradient, to integrate them into the forming 3D structures, taking into account the proportion present in the primary tumor tissues of each patient, for the 3D structures developed from their tumor.

Trial sites (1)

More University Hospital, Strasbourg, France trials in France

Other trials for the same condition